

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y	Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics.	Pathol Int	70(4)	191-198	2020
Muta H, So M, Sakurai K, Kardos J, Naiki H, Goto Y	Amyloid formation under complicated conditions in which $\beta_2$ -microglobulin coexists with its proteolytic fragments.	Biochemistry	58(49)	4925-4934	2019
Noji M, Sasahara K, Yamaguchi K, So M, Sakurai K, Kardos J, Naiki H, Goto Y	Heating during agitation of $\beta_2$ -microglobulin reveals that supersaturation breakdown is required for amyloid fibril formation at neutral pH.	J Biol Chem	294(43)	15826-15835	2019
Zhang C-M, Yamaguchi K, So M, Sasahara K, Ito T, Yamamoto S, Narita I, Kardos J, Naiki H, Goto, Y	Possible mechanisms of polyphosphate-induced amyloid fibril formation of $\beta_2$ -microglobulin.	Proc Natl Acad Sci U S A	116(26)	12833-12838	2019
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G	Expert Consensus Recommendations to Improve Diagnosis of ATTR Amyloidosis With Polyneuropathy.	J Neurol			2020 in press
Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y	Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics.	Pathol Int	70(4)	191-198	2020
Murakami T, Noguchi K, Hachiya N, Kametani F, Tasaki M, Nakaba S, Sassa Y, Yamashita T, Obayashi K, Ando Y, Hamamura M, Kanno T, Kawasaki K	Needle-shaped amyloid deposition in rat mammary gland: evidence of a novel amyloid fibril protein.	Amyloid	27(1)	25-35	2020
Nagase T, Iwaya K, Kogure K, Zako T, Misumi Y, Kikuchi M, Matsumoto K, Noritake M, Kawachi Y, Kobayashi M, Ando Y, Katsura Y	Insulin-derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases.	J Diabetes Investig		ISSN: 2040-1124	2019
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA,	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMIMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.	J Card Fail	25(11)	1-39	2019

Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM					
Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, Yamada M	Nationwide survey on cerebral amyloid angiopathy in Japan.	J Neurol Eur	26	1487-1493	2019
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.	ASNC/AHA/ASE/EANM/HFSA/ISA/ SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.	J Card Fail	25(11)	854-865	2019
Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K.	A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.	Circ J	84(1)	15-17	2019
Yamashita T, Ueda M, Nomura T, Okazaki T, Okada M, Tsuda Y, Inoue Y, Masuda T, Misumi Y, Takamatsu K, Obayashi K, Inomata Y, Hibi T, Ando Y	Natural history and long-term effects of variant protein reduction in non-V30M ATTR amyloidosis.	Neurology	93(16)	714-716	2019
Misumi Y, Ueda M, Masuda T, Tsuda Y, Nomura T, Okada M, Inoue Y, Tasaki M, Obayashi K, Yamashita T, Ando Y	Characteristics of acquired transthyretin amyloidosis: A case series and review of the literature.	Neurology	93(17)	1587-1596	2019
Ochi Y, Kubo T, Nakashima Y, Baba Y, Hirota T, Yamasaki N, Yamashita T, Ueda M, Ando Y, Kitaoka H	Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and	J Cardiol	75(1)	12-19	2019

	99mTc-pyrophosphate scintigraphy.				
Inoue Y, Ueda M, Masuda T, Misumi Y, Yamashita T, Ando Y	Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.	Mol Neurobiol	56(12)	8573-8588	2019
Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, Oda S, Utsunomiya D, Shiraishi S, Ueda M, Yamashita T, Sakamoto K, Yamamoto E, Kaikita K, Izumiya Y, Yamashita Y, Ando Y, Tsujita K	Combination of Commonly Examined Parameters Is a Useful Predictor of Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis.	Circ J	83(8)	1698-1708	2019
Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.	Blood	134(3)	320-323	2019
Ueda M, Okada M, Mizuguchi M, Kluge-Beckerman B, Kanenawa K, Isoguchi A, Misumi Y, Tasaki M, Ueda A, Kanai A, Sasaki R, Masuda T, Inoue Y, Nomura T, Shinriki S, Shuto T, Kai H, Yamashita T, Matsui H, Benson MD, Ando Y	A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.	J Biol Chem	294(29)	11259-11275	2019
Ueda M, Yamashita T, Misumi Y, Masuda T, Ando Y	Reader response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.	Neurology	93(5)	228-229	2019
Iwaya K, Zako T, Fukunaga J, Sörgjerd KM, Ogata K, Kogure K, Kosano H, Noritake M, Maeda M, Ando Y, Katsura Y, Nagase T	Toxicity of insulin-derived amyloidosis: a case report.	BMC Endocr Disord	19(1)	61	2019
Nakase T, Yamashita T, Matsuo Y, Nomura T, Sasada K, Masuda T, Misumi Y, Takamatsu K, Oda S, Furukawa Y,	Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S).	Intern Med	58(18)	2695-2698	2019

Obayashi K, Matsui H, Ando Y, Ueda M					
Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y	Correction to: Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.	Orphanet J Rare Dis	14(1)	111	2019
Nomura T, Ueda M, Tasaki M, Misumi Y, Masuda T, Inoue Y, Tsuda Y, Okada M, Okazaki T, Kanenawa K, Isoguchi A, Nakamura M, Obayashi K, Shinriki S, Matsui H, Yamashita T, Ando Y	New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis.	Orphanet J Rare Dis	14(1)	116	2019
Hayashi Y, Higashi T, Motoyama K, Jono H, Ando Y, Onodera R, Arima H	Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy.	Biol Pharm Bull	42(10)	1679-1688	2019
Hiroi T, Mushino T, Tanaka K, Furuya Y, Hori Y, Oiwa T, Kobata H, Yamashita Y, Hosoi H, Murata S, Nishikawa A, Tamura S, Takeuchi S, Nohgawa M, Yamashita T, Ando Y, Hata H, Sonoki T	AL amyloidosis diagnosed using anti-IGLL5 antibody: a case report.	Amyloid	26	111-112	2019
Yamashita T, Ohnishi K, Ueda M, Masuda T, Inoue Y, Misumi Y, Ueda A, Obayashi K, Takeya M, Ando Y	Transthyretin amyloid-related cerebral angitis after liver transplantation.	Amyloid	26	11-12	2019
Okuda Y, Yamada T, Ueda M, Ando Y	Nationwide survey of 199 patients with reactive amyloid a amyloidosis in Japan.	Amyloid	26	129	2019
Changes in nerve excitability indices in hereditary transthyretin amyloidosis.	Changes in nerve excitability indices in hereditary transthyretin amyloidosis.	Amyloid	26	9-10	2019
Yamaguchi I, Kokubo Y, Yamashita T, Ueda M, Okoshi T, Matsumine A, Ando Y, Naiki H	Class I small leucine-rich proteoglycans (SLRPs) colocalise with the A $\beta$ 2M amyloid deposits: implications for the roles of SLRP core proteins in the pathogenesis of dialysis-related amyloidosis.	Amyloid	26	140-141	2019

Kanenawa K, Ueda M, Isoguchi A, Nomura T, Tsuda Y, Masuda T, Misumi Y, Yamashita T, Ando Y	Histopathological and biochemical analyses of prostate corpora amyloacea.	Amyloid	26	160-161	2019
Ando Y, Ueda M, Jono H	Introduction.	Amyloid	26	1-3	2019
Obayashi K, Masuda T, Tasaki M, Ando Y, Ueda M	Evaluation of myoelectrical activities of descending colon by electrointestinogram in patients with ATTRm amyloidosis.	Amyloid	26	66	2019
Obayashi K, Masuda T, Tasaki M, Ando Y, Ueda M	Serum diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) in patients with ATTR-PN.	Amyloid	26	65	2019
Nagase T, Iwaya K, Zako T, Odaka T, Kogure K, Nemoto Y, Misumi Y, Noritake M, Ando Y, Katsura Y	Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis.	Amyloid	26	156-157	2019
Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Kawano Y, Okuno Y, Hata H, Matsuoka M, Yamashita T, Ueda M, Ando Y, Yamashita Y	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis.	Amyloid	26	91-92	2019
Masuda T, Ueda M, Misumi Y, Nomura T, Inoue Y, Isoguchi A, Kanenawa K, Tasaki M, Yamashita T, Sonoda Y, Obayashi K, Ando Y	Reduced intraepidermal nerve fibre density in patients with hereditary transthyretin amyloidosis.	Amyloid	26	79-80	2019
Ishii T, Sekijima Y, Ando Y	Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance.	Amyloid	26	45-46	2019
Inoue M, Ueda M, Higashi T, Anno T, Fujisawa K, Motoyama K, Mizuguchi M, Ando Y, Jono H, Arima H	Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis.	ACS Chem Neurosci	10(5)	2584-2590	2019
Tasaki M, Ueda M, Hoshii Y, Mizukami M, Matsumoto S, Nakamura M, Yamashita T, Ueda A, Misumi Y, Masuda T, Inoue Y, Torikai T, Nomura T, Tsuda Y, Kanenawa K, Isoguchi	A novel age-related venous amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1.	J Pathol	247(4)	444-455	2019

A, Okada M, Matsui H, Obayashi K, Ando Y					
安東 由喜雄	神経系のアミロイドーシスの最新の知見	医学のあゆみ	272	546-547	2020
一木 裕子, 安東 由喜雄	神経アミロイドーシス, 治療のめざましい進歩.	難病と在宅ケア	25	53-58	2020
山下 太郎, 植田 光晴, 安東 由喜雄	【U40世代が描く心不全診療の現状と未来-基礎研究を識り,臨床を素心深考する】心筋症 基礎編 心アミロイドーシス 治療の奏効する患者群は予測できますか? 基礎研究の見地からみた心アミロイドーシスの病態と治療	循環器ジャーナル	68	88-93	2020
安東 由喜雄, 松下博昭, 植田 光晴	神経系のアミロイドーシス ここまで進歩した治療と病態研究.	日本内科学会雑誌	108	1873-1882	2019
増田 曜章, 植田 光晴, 安東 由喜雄	検査からみる神経疾患 SUDOSCAN.	Clinical Neuroscience	37	1532-1533	2019
増田 曜章, 植田 光晴, 大林 光念, 安東 由喜雄	遺伝性トランスサイレチンアミロイドーシスの早期診断に有用な皮膚神経脱落の解析	ジャーナルフリー	56	264-268	2019
安東 由喜雄	むかしの頭で診ていませんか? 神経診療スッキリまとめました	臨床雑誌内科	124	2330-2330	2019
山下 太郎, 植田 光晴, 安東 由喜雄	脳神経と肝臓のクロストーク 遺伝性 ATTR 型脳アミロイド血管症と肝移植	臨床神経学	59	126	2019
安東 由喜雄, 田崎雅義	オミックス検査学における質量分析の役割-現状と展望 各種質量分析装置の特徴を活かした多角的なアミロイドーシス診断	臨床病理	67	32	2019
安東 由喜雄	【難治性ニューロパチーの新規治療】家族性アミロイドポリニューロパチー(遺伝性トランスサイレチン型アミロイドーシス)の新規治療の展望	脳神経内科	91	208-216	2019
井上 泰輝, 安東 由喜雄	【指定難病ペディア 2019】個別の指定難病 代謝・内分泌系 全身性アミロイドーシス	日本医師会雑誌	148	258-260	2019

植田 光晴, 安東 由喜雄	家族性アミロイドポリニューロパチー	ケアネット 希少疾患ライブラリー		( <a href="https://www.carenet.com/report/library/general/rare/fapp.html">https://www.carenet.com/report/library/general/rare/fapp.html</a> )	2019
三隅 洋平, 安東 由喜雄	siRNA を用いた核酸医薬品の開発状況	Medical Science Digest	45	17-20	2019
三隅 洋平, 増田 曜章, 植田 光晴, 野村 隼也, 磯口 藍斗, 井上 泰輝, 岡田 匡充, 山下 太郎, 安東 由喜雄	医原性 ATTR アミロイドーシスと遺伝性 ATTR アミロイドーシスの臨床像の比較検討	臨床神経学	59	240	2019
牧 美充, 野村 美和, 野口 悠, 池田 賢一, 渡邊 修, 増田 曜章, 安東 由喜雄, 高嶋 博	髄膜アミロイドーシスの 2 症例	臨床神経学	59	286	2019
増田 曜晴, 植田 光晴, 三隅 洋平, 野村 隼也, 磯口 藍斗, 井上 泰輝, 田崎 雅義, 山下 太郎, 大林 光念, 安東 由喜雄	遺伝性トランスサイレチンアミロイドーシスにおける体幹部神経障害の病態解析	臨床神経学	59	313	2019
山下 太郎, 植田 光晴, 野村 隼也, 岡崎 孝広, 岡田 匡充, 磯口 藍斗, 田崎 雅義, 津田 幸元, 井上 泰輝, 増田 曜章, 高松 孝太郎, 三隅 洋平, 大林 光念, 安東 由喜雄	野生型 ATTR アミロイドーシスにおける診断のための生検部位の検討	臨床神経学	59	313	2019
野村 隼也, 三隅 洋平, 田崎 雅義, 増田 曜章, 植田 光晴, 山下 太郎, 安東 由喜雄	遺伝性 ATTR アミロイドーシスにおける血管障害の解析	臨床神経学	59	314	2019
田崎 雅義, 植田 光晴, 大林 光念, 安東 由喜雄	EFEMP1 アミロイドの沈着頻度および至適病理学的診断法の検討	臨床病理	67	286	2019
城野 博史, 田崎 雅義, 山下 太郎, 大林 光念, 安東 由喜雄	臨床志向型プロテオーム研究の実践 アミロイドーシス病型診断におけるプロテオーム解析の実践	電気泳動	63	117	2019
田崎 雅義, 大林 光念, 安東 由喜雄	臨床志向型プロテオーム研究の実践 未知のアミロイド原因蛋白質も同定できる新たな質量分析診断法	電気泳動	63	118	2019

喜多 也寸志, 伊達紫, 中里 雅光, 山下太郎, 安東 由喜雄, 吉田 幸司, 寺澤 英夫, 清水 洋孝, 上原敏志	Val107ATTR 変異を認めた FAP 兄弟例	臨床神経学	59	674	2019
田崎 雅義, 植田 光晴, 星井 嘉信, 磯口 藍斗, 山下 太郎, 大林 光念, 安東 由喜雄	質量分析装置を用いた新規アミロイド原因蛋白質. EFEMP1 の同定	臨床化学	48	230	2019
田崎 雅義, 植田 光晴, 星井 嘉信, 磯口 藍斗, 山下 太郎, 大林 光念, 安東 由喜雄	質量分析装置を用いた新規アミロイド原因蛋白質. EFEMP1 の同定	臨床化学	48	285	2019
磯口 藍斗, 田崎 雅義, 植田 光晴, 星井 嘉信, 山下 太郎, 大林 光念, 安東 由喜雄	EFEMP1 のアミロイド線維形成能および本アミロイドの静脈細胞に与える影響	臨床化学	48	86	2019
井上 泰輝, 植田 光晴, 増田 曜章, 三隅 洋平, 山下 太郎, 安東 由喜雄	メマンチン塩酸塩はインスリン分解酵素の発現上昇を介し脳アミロイドアンギオパチーを抑制する	神経治療学	36	238	2019
柊中 智恵子, 山下太郎, 安東 由喜雄	遺伝性 ATTR アミロイドーシス国際交流会企画・運営の評価	日本遺伝看護学会誌	18	44	2019
津田 幸元, 向野 晃弘, 村上 慶高, 増田 曜章, 中原 圭一, 中根 俊成, 安東 由喜雄	ジストニア肢位に Muscle Afferent Block(MAB)が有効であった DRPLA の一例	臨床神経学	59	552	2019
城野 博史, 田崎 雅義, 山下 太郎, 大林 光念, 安東 由喜雄	臨床志向型プロテオーム研究の実践 アミロイドーシス病型診断におけるプロテオーム解析の実践	電気泳動	63	117	2019
増田 曜章, 植田 光晴, 永利 知佳子, 三隅 洋平, 井上 泰輝, 野村 隼也, 山下 太郎, 大林 光念, 安東 由喜雄	トランスサイレチン型家族性アミロイドポリニューロパチーの早期診断における瞳孔機能解析の有用性	自律神経	56	xxxvi	2019
武久 康, 野田 和代, 西村 広健, 山下 太郎, 安東 由喜雄	末梢神経障害をきたした AL アミロイドーシスの 70 歳女性	臨床神経学	59	390	2019
西 慎一, 藤井 秀毅, 島崎 千尋, 植田 光晴, 安東 由喜雄, 内木 宏延	AL アミロイドーシス症例の心エコー所見と腎機能・高血圧との関連	日本腎臓学会誌	61	370	2019



三隅 洋平, 安東 由 喜雄	心筋疾患 心アミロイドーシス	医学のあゆ み	268	737-742	2019
Hamaguchi, T, Komatsu J, Sakai K, Noguchi-Shinohara M, Aoki S, Ikeuchi T, Yamada M	Cerebral hemorrhagic stroke associated with cerebral amyloid angiopathy in young adults about 3 decades after neurosurgeries in their infancy.	J Neurol Sci	399	3-5	2019
Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, Yamada M	Nationwide survey on cerebral amyloid angiopathy in Japan.	Eur J Neurol	26	1487-1493	2019
Yamada M, Hamaguchi T, Sakai K	Acquired cerebral amyloid angiopathy: an emerging concept.	Prog Mol Biol Transl Sci	168	85-95	2019
Aizawa S, Okada T, Keino-Masu K, Doan TH, Koganezawa T, Akiyama M, Tamaoka A, Masu M	Abnormal Pyramidal Decussation and Bilateral Projection of the Corticospinal Tract Axons in Mice Lacking the Heparan Sulfate Endosulfatases, Sulf1 and Sulf2.	Front Mol Neurosci	12	333	2020
Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatiirelin Study Group	Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.	J Neurol Neurosurg Psychiatry	10	1136	2020
Tamaoka A	Current Clinical Trials in the Treatment of Alzheimer's Disease.	Brain and Nerve	72(1)	23-34	2020
Shioya A, Takuma H, Takahashi T, Ishii A, Aoki M, Tamaoka A	Radiological findings in siblings with dysferlin mutation with diverse phenotype.	J Neurol Sci	409	116579	2020
Ishii K, Yamamoto F, Homma S, Okada Y, Nakamichi K, Saijo M, Tamaoka A	Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.	BMC Neurol	19(1)	263-269	2019
Ishii A, Nohara S, Yamamoto F, Tsuji H, Yatsuga S, Koga Y, Tamaoka A	Potentially confounding variables of mitochondria biomarker GDF-15.	Neuromusc Disord	29(S1)	S56	2019
Hosoi T, Ishii K, Tozaka N, Kishida D, Sekijima Y, Tamaoka A	Familial Mediterranean Fever is Important in the Differential Diagnosis of Recurrent Aseptic Meningitis in Japan.	Intern Med	59(1)	125-128	2020
Hosaka T, Nakamagoe K, Tozaka N, Aizawa S, Tamaoka A	Steroid pulse therapy of radiological disease activity without clinical relapse in CLIPPERS.	Neurol Sci	41(3)	709-711	2020

Nohara S, Ishii A, Yamamoto F, Yanagiha K, Moriyama T, Tozaka N, Miyake Z, Yatsuga S, Koga Y, Hosaka T, Terada M, Yamaguchi T, Aizawa S, Mamada N, Tsuji H, Tomidokoro Y, Nakamagoe K, Ishii K, Watanabe M, Tamaoka A	GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis.	J Neurol Sci	405	116429	2019
Shioya A, Mashiko R, Shiigai M, Nakai Y, Takahashi N, Kobayashi H, Irie T, Tamaoka A	Dural Sinus Thrombosis with Nonsymptomatic Persistent Falcine Sinus: A Case Report.	J Stroke Cerebrovasc Dis	28(11)	104309	2019
Miyake Z, Tomidokoro Y, Nohara S, Tamaoka A	Chronic myelitis associated with zoster sine herpette: A case report.	Medicine (Baltimore)	98(32)	E16671	2019
Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N	Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey.	Mol Genet Metab Rep	20	100496	2019
Tomono T, Hirai Y, Chono H, Mineno J, Ishii A, Onodera M, Tamaoka A, Okada T	Infectivity assessment of recombinant adeno-associated virus (rAAV) and wild-type AAV (wtAAV) exposed to various diluents and environmental conditions.	Hum Gene Ther Methods	30(4)	137-143	2019
Hosaka T, Yamashita T, Tamaoka A, Kwak S	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases.	Int J Mol Sci	20(13)	E3148	2019
Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, Yamada M	Nationwide survey on cerebral amyloid angiopathy in Japan.	Eur J Neurol	26(12)	1487-1493	2019
Taniguchi K, Yamamoto F, Arai T, Yang J, Sakai Y, Itoh M, Mamada N, Sekiguchi M, Yamada D, Saitoh A, Kametani F, Tamaoka A, Araki YM, Wada K, Mizusawa H, Araki W	Tyrosol Reduces Amyloid- $\beta$ Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer's Disease Model Mice.	J Alzheimers Dis	70(3)	937-952	2019

Nakamagoe K, Yamada S, Kawakami R, Koganezawa T, Tamaoka A	Abnormal Saccadic Intrusions with Alzheimer's Disease in Darkness.	Curr Alzheimer Res	16(4)	293-301	2019
Miyake Z, Tomidokoro Y, Tsurubuchi T, Matsumura A, Sakamoto N, Noguchi M, Tamaoka A	Intravascular large B-cell lymphoma presenting with hearing loss and dizziness: A case report.	Medicine (Baltimore)	98(7)	E14470	2019
Nohara S, Tsuji H, Tamaoka A	Alien leg phenomenon in corticobasal syndrome.	J Clin Neurosci	64	254-255	2019
玉岡晃	アルツハイマー病 - 臨床試験の現状と展望 .	BRAIN and NERVE	72(1)	23-34	2020
玉岡晃	認知症の発症予防の現状 .	MEDECAL REHABILITATION	241	1-5	2019
寺田真, 玉岡晃	シヌクレインのプリオン様作用	医学のあゆみ	271(7)	668-670	2019
玉岡晃	抗アミロイド 抗体療法の現況	Neurodiem	-	-	2019
森山哲也, 山本詞子, 石井一弘, 玉岡晃	水頭症を呈したサイコイドーシス .	日本医事新報	4976	10-11	2019
森山哲也, 渡邊雅彦, 玉岡晃	パーキンソニズムを呈した硬膜動静脈瘻	日本医事新報	4966	8-10	2019
玉岡晃	アルツハイマー病	CLINICAL NEUROSCIENCE	37(7)	851-853	2019
玉岡晃	脂質異常症	Geriatric Medicine	57(4)	335-338	2019
森山哲也, 中馬越清隆, 玉岡晃	バセドウ病を合併し、抗 CCP 抗体が陽性であった無菌性髄膜炎	日本医事新報	4949	10-11	2019
Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, Hoshino	Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.	CEN Case Reports	9	6-10	2020

J, Takaichi K, Wake A, Ohashi K, Fujii T, Ubara Y					
Nishi S, Yamamoto S, Hoshino J, Takaichi K, Naiki H	The features of bone articular lesions in dialysis-related amyloidosis (DRA) and criteria for the clinical diagnosis of DRA.	Renal Replacement Therapy	5(10)	1-8	2019
Takase H, Tanaka M, Nakamura Y, Morita S, Yamada T, Mukai T	Effects of lipid composition on the structural properties of human serum amyloid A in reconstituted high-density lipoprotein particles.	Chem Phys Lipids	221	8-14	2019
Kotani K, Yamada S, Takahashi H, Iwazu Y, Yamada T	The ratio of oxidized lipoprotein(a) to native Lipoprotein(a) and the endothelial function in patients with type 2 diabetes mellitus.	Int J Mol Sci	20(19)		2019
若松弘之、築瀬直穂、美、日高裕介、鯉淵晴美、岩津好隆、山本さやか、谷口信行、山田俊幸	免疫固定電気泳動法システムでのIgA型M蛋白の軽鎖同定における問題点。	臨床病理	67	675-678	2019
Yashiro M, Ohya M, Mima T, Nakashima Y, Kawakami K, Yamamoto S, Kobayashi S, Yano T, Tanaka Y, Sonou T, Tatsuta K, Negi S, Shigematsu T	Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor.	J Pharmaceutic Biomed Analysis			2020 in press
Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Shinoda A, Akizawa T	Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.	Nephrology (Carlton)			2020 in press
Okuda Y	AA amyloidosis – Benefits and prospects of IL-6 Inhibitors.	Mod Rheumatol	29	268-274	2019
Nishi S, Yamamoto S, Hoshino J, Takaichi K, Naiki H	The features of bone articular lesions in dialysis-related amyloidosis (DRA) and criteria for the clinical diagnosis of DRA.	Renal Replacement Therapy	5(10)	1-8	2019
Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).	Int J Hematol	109(5)	509-538	2019
Ueno S, Nozaki J, Kusano S, Kawano Y, Kikukawa Y, Okuno Y, Hata H, Matsuoka M, Uchiba M	Spontaneous remission of acquired factor XIII inhibitor concurrent to development of IgA-λ type multiple myeloma.	Jpn J Clin Hematol	60(10)	1443-1448	2019
Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N,	Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.	Cancer Sci	110(10)	3275-3287	2019

Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y					
Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y	The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach.	Cell Rep	29(3)	724-735	2019
Koike H, Fukami Y, Nishi R, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome.	J Neurol Neurosurg Psychiatry			2020 in press
Koike H, Ikeda S, Fukami Y, Nishi R, Kawagashira Y, Iijima M, Nakamura T, Kuwahara M, Kusunoki S, Katsuno M, Sobue G	Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies.	J Neurol Sci	408	116509	2020
Koike H, Katsuno M	Expanding the spectrum of transthyretin amyloidosis.	Muscle Nerve	61(1)	3-4	2020
Koike H, Katsuno M, Sobue G	New teased-fibre definitions represent specific mechanisms of neuropathy.	J Neurol Neurosurg Psychiatry	90(2)	124	2019
Koike H, Fukami Y, Nishi R, Kawagashira Y, Iijima M, Sobue G, Katsuno M	Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis.	Neurol Clin Neurosci	7	166-173	2019
Koike H, Katsuno M	Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights.	Biomedicines	7(1)	E11	2019
Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.	Amyloid	26(sup1)	26	2019
Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Cardiac and peripheral vasomotor autonomic functions in hereditary transthyretin amyloidosis with non-Val30Met mutation.	Amyloid	26(sup1)	13-14	2019

Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Yasuda T, Mukai E, Date Y, Shiomi K, Nakazato M, Katsuno M, Sobue G	Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly, Val94Gly, and Val30Met).	Amyloid	26(sup1)	24-25	2019
Nishi R, Koike H, Ohyama K, Fukami Y, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Differential clinicopathological features of EGPA-associated neuropathy with and without ANCA.	Neurology			2020 in press
Fukami Y, Koike H, Iijima M, Hagita J, Niwa H, Nishi R, Kawagashira Y, Katsuno M	Demyelinating neuropathy due to intravascular large B-cell lymphoma: a case report.	Intern Med	59(3)	435-438	2020
Adams D, Koike H, Slama M, Coelho T	Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.	Nat Rev Neurol	15(7)	387-404	2019
Ikeda S, Koike H, Nishi R, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy.	J Neurol Neurosurg Psychiatry	90(9)	988-996	2019
Nakamura T, Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G	Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation.	Amyloid	26(sup1)	6	2019
Sone J, Mitsuhashi S, Fujita A, Mizuguchi T, Hamanaka K, Mori K, Koike H, Hashiguchi A, Takashima H, Sugiyama H, Kohno Y, Takiyama Y, Maeda K, Doi H, Koyano S, Takeuchi H, Kawamoto M, Kohara N, Ando T, Ieda T, Kita Y, Kokubun N, Tsuboi Y, Katoh K, Kino Y, Katsuno M, Iwasaki Y, Yoshida M, Tanaka F, Suzuki IK, Frith MC, Matsumoto N, Sobue G	Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease.	Nat Genet	51(8)	1215-1221	2019
Mizuno Y, Shinoda K, Watanabe M, Ogata H, Isobe N, Matsushita T, Yamasaki R, Tanaka K, Koike H, Katsuno M, Kira JI	Intractable axonal neuropathy with multifocal peripheral nerve swelling in neuromyelitis optica spectrum disorders: a case report.	Mult Scler Relat Disord	35	16-18	2019

Kondo N, Tohnai G, Sahashi K, Iida M, Kataoka M, Nakatsuji H, Tsutsumi Y, Hashizume A, Adachi H, Koike H, Shinjo K, Kondo Y, Sobue G, Katsuno M	DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5.	EMBO Mol Med	11(5)	e8547	2019
Ando T, Iijima M, Fukami Y, Nishi R, Ikeda S, Yokoi S, Kawagashira Y, Koike H, Muro Y, Katsuno M	Vasculitic neuropathy with anti-phosphatidylserine/prothrombin complex antibody.	Muscle Nerve	59(6)	E44-E46	2019
Sato T, Terasawa Y, Higa H, Matsuno H, Arai A, Omoto S, Mitsumura H, Toyoda C, Koike H, Iguchi Y	Nerve ultrasound, electrophysiological, and clinical changes in treatment-naive chronic inflammatory demyelinating polyneuropathy: a case report.	J Clin Neurophysiol	36(1)	82-84	2019
加納裕也, 加藤秀紀, 小池春樹, 勝野雅央, 小栗卓也, 湯浅浩之	神経生検で血管炎の所見を認めた, 強皮症に伴う多発性単ニューロパチーの一例.	臨床神経学	59(9)	604-606	2019
小池春樹	限局性血管炎と末梢神経障害.	脳神経内科	91(3)	295-300	2019
小池春樹	代謝性・栄養性・薬剤性ニューロパチー.	日本内科学会雑誌	108(8)	1530-1537	2019
小池春樹	体幹部のニューロパチー.	脊椎脊髄ジャーナル	32(1)	27-32	2019
小池春樹	栄養欠乏による神経障害	CLINICAL NEUROSCIENCE	37(11)	1373-1375	2019
小池春樹, 祖父江元	慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー.	日本医師会雑誌	148(特別号 1)	S86-S88	2019
小池春樹	ビタミン B1 欠乏	CLINICAL NEUROSCIENCE	38(2)	251-253	2020
Iida S, Shimazaki C, Abe M, Nakaseko C	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.	Int J Hematol	109(6)	633-640	2019
Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).	Int J Hematol	109(5)	509-538	2019

Kamiya Y, Chou T, Murakami H, Handa H, Ozaki S, Shimazaki C, Fuchida SI, Okada J, Itoh J, Sugiyama S, Shimizu K	Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay.	Hematol Oncol	37(3)	316-318	2019
Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C	Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.	ESC Heart Fail	6(1)	232-236	2019
島崎千尋	本邦におけるALアミロイドーシス-全国疫学調査からみた診断と治療の現状-	臨床血液	60(8)	973-978	2019
Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).	Int J Hematol	109(5)	509-538	2019
Iida S, Shimazaki C, Abe M, Nakaseko C	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.	Int J Hematol	109(6)	633-640	2019
Murase T, Ri M, Narita T, Fujii K, Masaki A, Iida S, Inagaki H	Immunohistochemistry using bone marrow paraffin sections is a reliable screening tool for identification of <i>CCND1</i> , <i>NSD2</i> , and <i>MAF</i> rearrangements in multiple myeloma.	Cancer Sci	110(8)	2600-2606	2019
Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S	Serum lipidomics for exploring biomarker of bortezomib therapy in patients with multiple myeloma.	Cancer Sci	110(10)	3267-3274	2019
Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y	Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics.	Pathol Int			2020 in press
González-Duarte A, Berk J, Quan D, Mauermann M, Schmidt H, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição I, Kristen A, Coelho T, Cauquil C, Tard C, Merkel M, Aldinc E, Chen J, Sweetser M, Wang J, Adams D	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.	J Neurol	267(3)	703-712	2020



Ochi Y, Kubo T, Nakashima Y, Baba Y, Hirota T, Yamasaki N, Yamashita T, Ueda M, Ando Y, Kitaoka H	Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and <sup>99m</sup> Tc-pyrophosphate scintigraphy.	J Cardiol	75(1)	12-19	2020
Inoue Y, Ueda M, Masuda M, Misumi Y, Yamashita T, Ando Y	Memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, attenuates cerebral amyloid angiopathy by increasing insulin-degrading enzyme expression.	Mol Neurobiol	56(12)	8573-8588	2019
Sakai K, Ueda M, Fukushima W, Tamaoka A, Shoji M, Ando Y, Yamada M	Nationwide survey on cerebral amyloid angiopathy in Japan.	Eur J Neurol	26(12)	1487-1493	2019
Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K	A statement for the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis.	Circ J	84(1)	15-17	2019
Misumi Y, Ueda M, Masuda T, Tsuda Y, Nomura T, Okada M, Inoue Y, Tasaki M, Obayashi K, Yamashita T, Ando Y	Characteristics of acquired transthyretin amyloidosis A case series and review of the literature.	Neurology	93(17)	e1587-e1596	2019
Yamashita T, Ueda M, Nomura T, Okazaki T, Okada M, Tsuda Y, Inoue Y, Masada T, Misumi Y, Takamatsu K, Obayashi K, Inomata Y, Hibi T, Ando Y	Natural history and long-term effects of variant protein reduction in non-V30M ATTR amyloidosis.	Neurology	93(16)	714-716	2019
Nakase T, Yamashita T, Matsuo Y, Nomura T, Sasada K, Masuda T, Misumi Y, Takamatsu K, Oda S, Furukawa Y, Obayashi K, Matsui H, Ando Y, Ueda M	Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y114S).	Intern Med	58(18)	2695-2698	2019
Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: a prospective study in 206 patients.	Blood	134(3)	320-323	2019

Ueda M, Okada M, Mizuguchi M, Kluge-Beckerman B, Kanenawa K, Isoguchi A, Misumi Y, Tasaki M, Ueda A, Kanai A, Sasaki R, Masuda T, Inoue Y, Nomura T, Shinriki S, Shuto T	A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.	J Biol Chem	294(29)	11259-11275	2019
Ueda M, Yamashita T, Misumi Y, Masuda T, Ando Y	Reader response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.	Neurology	93(5)	228-229	2019
Yamashita T, Ueda M, Misawa S, Inoue Y, Masuda T, Misumi Y, Takamatsu K, Obayashi K, Kuwabara S, Ando Y	Changes in nerve excitability indices in hereditary transthyretin amyloidosis.	Amyloid	26(sup1)	9-10	2019
Yamashita T, Ohnishi K, Ueda M, Masuda T, Inoue Y, Misumi Y, Ueda A, Obayashi K, Takeya M, Ando Y	Transthyretin amyloid-related cerebral angiitis after liver transplantation.	Amyloid	26(sup1)	11-12	2019
Obayashi K, Masuda T, Tasaki M, Ando Y, Ueda M	Serum diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) in patients with ATTR-PN.	Amyloid	26(sup1)	65	2019
Obayashi K, Masuda T, Tasaki M, Ando Y, Ueda M	Evaluation of myoelectrical activities of descending colon by electrointestinogram in patients with ATTRm amyloidosis.	Amyloid	26(sup1)	66	2019
Isoguchi A, Ueda M, Kanenawa K, Masuda T, Misumi Y, Yamashita T, Obayashi K, Ando Y	A novel transgenic mouse model expressing mutant TTR gene causing oculoleptomeningeal type of ATTRm amyloidosis.	Amyloid	26(sup1)	69	2019
Masuda T, Ueda M, Misumi Y, Nomura T, Inoue Y, Isoguchi A, Kanenawa K, Tasaki M, Yamashita T, Sonoda Y, Obayashi K, Ando Y	Reduced intraepidermal nerve fibre density in patients with hereditary transthyretin amyloidosis.	Amyloid	26(sup1)	79-80	2019
Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Kawano Y, Okuno Y, Hata H, Matsuoka M, Yamashita T, Ueda M, Ando Y, Yamashita Y	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis.	Amyloid	26(sup1)	91-92	2019
Okuda Y, Yamada T, Ueda M, Ando Y	Nationwide survey of 199 patients with reactive amyloid A amyloidosis in Japan.	Amyloid	26(sup1)	129	2019

Yamaguchi I, Kokubo Y, Yamashita T, Ueda M, Okoshi T, Matsumine A, Ando Y, Naiki H	Class I small leucine-rich proteoglycans (SLRPs) colocalise with the A $\beta$ 2M amyloid deposits: implications for the roles of SLRP core proteins in the pathogenesis of dialysis-related amyloidosis.	Amyloid	26(sup1)	140-141	2019
Kanenawa K, Ueda M, Isoguchi A, Nomura T, Tsuda Y, Masuda T, Misumi Y, Yamashita T, Ando Y	Histopathological and biochemical analyses of prostate corpora amylacea.	Amyloid	26(sup1)	160-161	2019
Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, Oda S, Utsunomiya D, Shiraishi S, Ueda M, Yamashita T, Sakamoto K, Yamamoto E, Kaikita K, Izumiya Y, Yamashita Y, Ando Y, Tsujita K	Combination of commonly examined parameters is a useful predictor of positive 99mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis.	Circ J	83(8)	1698-1708	2019
Nomura T, Ueda M, Tasaki M, Misumi Y, Masuda T, Inoue Y, Tsuda Y, Okada M, Okazaki T, Kanenawa K, Isoguchi A, Nakamura M, Obayashi K, Shinriki S, Matsui H, Yamashita T, Ando Y	New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis.	Orphanet J Rare Dis	14(1)	116	2109
Tasaki M,* Ueda M,* Hoshii Y, Mizukami M, Matsumoto S, Nakamura M, Yamashita T, Ueda A, Misumi Y, Masuda T, Inoue Y, Torikai T, Nomura T, Tsuda Y, Kanenawa K, Isoguchi A, Okada M, Matsui H, Obayashi K, Ando Y (*contributed equally).	A novel age-related venous amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1.	J Pathol	247(4)	444-455	2019
Inoue M, Ueda M, Higashi T, Anno T, Fujisawa K, Motoyama K, Mizuguchi M, Ando Y, Jono H, Arima H	Therapeutic potential of Polyamidoamine Dendrimer for amyloidogenic transthyretin amyloidosis.	ACS Chem Neurosci	10(5)	2584-2590	2019
植田光晴, 三隅洋平, 増田曜章, 緒方正輝, 城野博史, 齋藤秀之, 山下太郎, 安東由喜雄	パチシラン	日本病院薬剤師会雑誌	56(4)	421-425	2020

植田光晴	家族性アミロイドポリニューロパチー．特集：神経疾患の現在とこれから．	内科	123(6)	1263-1266	2019
植田光晴	野生型トランスサイレチン（TTR）が原因となる老人性全身性アミロイドーシス（SSA）の心病変．	Heart View	23(8)	763-768	2019
Yamanouchi M, Furuichi K, Hoshino J, Toyama T, Hara A, Shimizu M, Kinowaki K, Fujii T, Ohashi K, Yuzawa Y, Kitamura H, Suzuki Y, Sato H, Uesugi N, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Samejima K, Kohagura K, Shibagaki Y, Mise K, Makino H, Matsuo S, Ubara Y, Wada T	Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study.	Diabetes Care	42(5)	891-902	2019
Yabuuchi J, Hoshino J, Mizuno H, Ozawa Y, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hayami N, Yamanouchi M, Hasegawa E, Suwabe T, Sawa N, Fujii T, Ohashi K, Takaichi K, Ubara Y	Immunoglobulin G subclass 3 in ISN/RPL lupus nephritis classification.	Clin Nephrol	91	32-39	2019
Takada D, Hoshino J, Fujii T, Usui J, Fujii T, Ohashi K, Takaichi K, Suzuki S, Yamagata K, Ubara Y	Association between renal outcome and the number of steroid pulse therapies after tonsillectomy in patients with IgA nephropathy.	Clin Exp Nephrol	23	335-341	2019
Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, Hoshino J, Takaichi K, Wake A, Ohashi K, Fujii T, Ubara Y	Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.	CEN Case Rep		31522370	2020
Kuroda T, Honma M, Mori Y, Futamura A, Sugimoto A, Yano S, Kinno R, Murakami H, Ono K	Increased Presence of Cerebral Microbleeds Correlates with Ventricular Enlargement and Increased White Matter Hyperintensities in Alzheimer's Disease.	Front Aging Neurosci	12		2020 In press
Ono K, Tsuji M	Protofibrils of Amyloid- $\beta$ are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.	Int J Mol Sci	21(3)		2020 In press

Ono K, Zhao D, Wu Q, Simon J, Wang J, Radu A, Pasinetti GM	Pine Bark Polyphenolic Extract Attenuates Amyloid- $\beta$ and Tau Misfolding in a Model System of Alzheimer's Disease Neuropathology.	J Alzheimers Dis	73(4)	1597-1606	2020
Abe K, Shang J, Shi X, Yamashita T, Hishikawa N, Takemoto M, Morihara R, Nakano Y, Ohta Y, Deguchi K, Ikeda M, Ikeda Y, Okamoto K, Shoji M, Takatama M, Kojo M, Kuroda T, Ono K, Kimura N, Matsubara E, Osakada Y, Wakutani Y, Takao Y, Higashi Y, Asada K, Senga T, Lee LJ, Tanaka K	A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.	J Alzheimers Dis	73(1)	217-227	2020
Hase T, Shishido S, Yamamoto S, Yamashita R, Nukima H, Taira S, Toyoda T, Abe K, Hamaguchi T, Ono K, Noguchi-Shinohara M, Yamada M, Kobayashi S	Rosmarinic acid suppresses Alzheimer's disease development by reducing amyloid $\beta$ aggregation by increasing monoamine secretion.	Sci Rep	9(1)	8711	2019
Ono K, Tsuji M	Pharmacological Potential of Cilostazol for Alzheimer's Disease.	Front Pharmacol	10	559	2019
Yasumoto T, Takamura Y, Tsuji M, Watanabe-Nakayama T, Imamura K, Inoue H, Nakamura S, Inoue T, Kimura A, Yano S, Nishijo H, Kiuchi Y, Teplow DB, Ono K	High molecular weight amyloid $\beta_{1-42}$ oligomers induce neurotoxicity via plasma membrane damage.	FASEB J	33(8)	9220-9234	2019
Nomoto S, Kinno R, Ochiai H, Kubota S, Mori Y, Futamura A, Sugimoto A, Kuroda T, Yano S, Murakami H, Shirasawa T, Yoshimoto T, Minoura A, Kokaze A, Ono K	The relationship between thyroid function and cerebral blood flow in mild cognitive impairment and Alzheimer's disease.	PLoS One	14(4)	e0214676	2019
黒田岳志, 小野賢二郎	アルツハイマー病における brain lymphatic drainage system の障害.	認知症の最新医療	9(4)	212-213	2019

杉本あずさ, 小野賢二郎	A 凝集制御薬.	認知症の最新医療	9(3)	138-142	2019
杉本あずさ, 小野賢二郎	抗アミロイド 系薬剤.	老年精神医学雑誌	30(6)	653-662	2019
Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, Ando Y	Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics.	Pathol Int			2020 in press
Ichimata S, Hata Y, Abe R, Yoshinaga T, Katoh N, Kametani F, Yazaki M, Sekijima Y, Ehara T, Nishida N	An autopsy case of amyloid tubulopathy exhibiting characteristic spheroid-type deposition.	Virchows Arch			2020 in press
Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.	Amyloid	26	10-14	2019
Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K	A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis.	Circ J	84 (1)	15-17	2019
Ishii T, Sekijima Y, Ando Y	Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance.	Amyloid	26(sup1)	45-46	2019
Kodaira M, Ohashi N, Morita H, Sekijima Y	Length-dependent truncal A $\delta$ -fiber dysfunction in hereditary transthyretin amyloidosis: An intra-epidermal electrical stimulation study.	Clin Neurophysiol	130(6)	903-910	2019
Kozuka A, Koyama J, Sekijima Y, Ikeda U	Quantitative analysis of endocardial and epicardial left ventricular myocardial deformation in patients with cardiac amyloidosis.	Shinshu Med J	67	49-60	2019
Koyama J, Minamisawa M, Sekijima Y, Kuwahara K, Katsuyama T, Maruyama K	Role of echocardiography in assessing cardiac amyloidoses: a systematic review.	J Echocardiogr	17(2)	64-75	2019
Miyake Z, Nakamagoe K, Ezawa N, Yoshinaga T, Hashimoto R, Sato T, Sekijima Y, Tamaoka A	Late-onset transthyretin (TTR)-familial amyloid polyneuropathy (FAP) with a long disease duration from non-endemic areas in Japan.	Intern Med	58(5)	713-718	2019

Ohashi N, Kodaira M, Morita H, Sekijima Y	Electrophysiological demyelinating features in hereditary ATTR amyloidosis.	Amyloid	26(1)	15-23	2019
Sekijima Y, Mundayat R, Ishii T, Ando Y	The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan.	Amyloid	26(sup1)	61-62	2019
Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C	Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.	ESC Heart Fail	6(1)	232-236	2019
Yamada Y, Fukushima T, Kodama S, Shimizu H, Kakita A, Makino K, Sekijima Y	A case of cerebral amyloid angiopathy-type hereditary ATTR amyloidosis with Y69H (p.Y89H) variant displaying transient focal neurological episodes as the main symptom.	Amyloid	26(4)	251-252	2019
関島良樹	遺伝性 ATTR アミロイドーシス (家族性アミロイドポリニューロパチー)	Clinical Neuroscience	38(3)	336-338	2020
関島良樹	老化とアミロイドーシス	信州医学雑誌	67	79-80	2019
関島良樹	アミロイドーシスと感染症	Neuroinfection	24	24-28	2019
Yamamoto T, Endo J, Kataoka M, Matsuhashi T, Katsumata Y, Shirakawa K, Isobe S, Moriyama H, Goto S, Shimanaka Y, Kono N, Arai H, Shinmura K, Fukuda K, Sano M.	Palmitate induces cardiomyocyte death via inositol requiring enzyme-1 (IRE1)-mediated signaling independent of X-box binding protein 1 (XBP1).	Biochem Biophys Res Commun	526(1)	122-127	2020
Yamashita K, Ito K, Endo J, Matsuhashi T, Katsumata Y, Yamamoto T, Shirakawa K, Isobe S, Kataoka M, Yoshida N, Goto S, Moriyama H, Kitakata H, Mitani F, Fukuda K, Goda N, Ichihara A, Sano M	Adrenal cortex hypoxia modulates aldosterone production in heart failure.	Biochem Biophys Res Commun	524(1)	184-189	2020

Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K	A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.	Circ J	84(1)	15-17	2019
Hiraide T, Kataoka M, Suzuki H, Aimi Y, Chiba T, Isobe S, Katsumata Y, Goto S, Kanekura K, Yamada Y, Moriyama H, Kitakata H, Endo J, Yuasa S, Arai Y, Hirose N, Satoh T, Hakamata Y, Sano M, Gamou S, Kosaki K, Fukuda K	Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension.	J Heart Lung Transplant	39(2)	103-112	2019
Yoshida N, Endo J, Kinouchi K, Kitakata H, Moriyama H, Kataoka M, Yamamoto T, Shirakawa K, Morimoto S, Nishiyama A, Hashiguchi A, Higuchi I, Fukuda K, Ichihara A, Sano M	(Pro)renin receptor accelerates development of sarcopenia via activation of Wnt/YAP signaling axis.	Aging Cell	18(5)	e12991	2019
Yamamoto T, Endo J, Kataoka M, Matsuhashi T, Katsumata Y, Shirakawa K, Yoshida N, Isobe S, Moriyama H, Goto S, Yamashita K, Ohto-Nakanishi T, Nakanishi H, Shimanaka Y, Kono N, Shinmura K, Arai H, Fukuda K, Sano M	Sirt1 counteracts decrease in membrane phospholipid unsaturation and diastolic dysfunction during saturated fatty acid overload.	J Mol Cell Cardiol	133	1-11	2019
Matsuhashi T, Endo J, Katsumata Y, Yamamoto T, Shimizu N, Yoshikawa N, Kataoka M, Isobe S, Moriyama H, Goto S, Fukuda K, Tanaka H, Sano M	Pressure overload inhibits glucocorticoid receptor transcriptional activity in cardiomyocytes and promotes pathological cardiac hypertrophy.	J Mol Cell Cardiol	130	122-130	2019
Sano M, Goto S	Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.	Circulation	139(17)	1985-1987	2019



Isobe S, Kataoka M, Endo J, Moriyama H, Okazaki S, Tsuchihashi K, Katsumata Y, Yamamoto T, Shirakawa K, Yoshida N, Shimoda M, Chiba T, Masuko T, Hakamata Y, Kobayashi E, Saya H, Fukuda K, Sano M	Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and $\alpha$ CT in Pulmonary Hypertension.	Am J Respir Cell Mol Biol	61(3)	367-379	2019
Goto S, Kimura M, Katsumata Y, Goto S, Kamatani T, Ichihara G, Ko S, Sasaki J, Fukuda K, Sano M	Artificial intelligence to predict needs for urgent revascularization from 12-lead electrocardiography in emergency patients.	PLoS One	14(1)	e0210103	2019
Tahara A, Tahara N, Maeda-Ogata S, Bekki M, Sugiyama Y, Honda A, Abe T, Yamagishi S-I, Fukumoto Y	Brown adipose tissue activation in severe heart failure.	Eur Heart J			2020 in press
Yanagisawa K, Sotokawauchi A, Nishino Y, Matsui T, Tahara N, Yamagishi SI	Albuminuria-lowering effect of sodium-glucose cotransporter 2 inhibitors could be partly attributable to the attenuation of tubular damage in type 2 diabetic patients.	Diabetes Metab Res Rev			2020 in press
Tahara N, Dobashi H, Fukuda K, Funauchi M, Hatano M, Ikeda S, Joho S, Kihara Y, Kondo T, Matsushita M, Minamino T, Nakanishi N, Okano Y, Ozaki Y, Saji T, Sakai S, Tanabe N, Watanabe H, Yamada H, Yoshioka K, Hatta M, Sasayama S	Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.	Curr Med Res Opin			2020 in press
Bekki M, Tahara N, Tahara A, Maeda-Ogata S, Sugiyama Y, Honda A, Igata S, Harada A, Hirakawa Y, Kurata S, Fujimoto K, Abe T, Fukumoto Y, Ueno T	Switching from clopidogrel to prasugrel resolves vascular inflammation in patients receiving long-term aspirin plus clopidogrel therapy after coronary stent implantation.	J Nucl Cardiol			2020 in press
Sugiyama Y, Tahara N, Bekki M, Tahara A, Honda A, Ogata-Maeda S, Sun J, Igata S, Fukumoto Y	Long-term survival outcome for pre-capillary pulmonary hypertension at a Japanese single center.	Can J Physiol Pharmacol			2020 in press
Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K	A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.	Circ J	84(1)	15-17	2019

Tahara N, Nitta Y, Bekki M, Tahara A, Maeda-Ogata S, Sugiyama Y, Honda A, Igata S, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Matsui T, Yamagishi SI, Fukumoto Y	Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients.	J Nucl Cardiol			2019 in press
Tahara A, Tahara N, Maeda-Ogata S, Bekki M, Sugiyama Y, Sun J, Honda A, Igata S, Fukumoto Y	Clinical hallmarks making diagnosis of infective endocarditis.	J Nucl Cardiol			2019 in press
Ito S, Tahara N, Hirakata S, Kaieda S, Tahara A, Maeda-Ogata S, Bekki M, Sugiyama Y, Honda A, Igata S, Kuromatsu R, Nakashima O, Fukumoto Y	Signal intensity of superb micro-vascular imaging associates with the activity of vascular inflammation in Takayasu arteritis.	J Nucl Cardiol			2019 in press
Tahara N, Kojima R, Yoshida R, Bekki M, Sugiyama Y, Tahara A, Maeda S, Honda A, Igata S, Nakamura T, Sun J, Matsui T, Fukumoto Y, Matsui T, Yamagishi SI	Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine.	Rejuvenation Res	22(5)	431-438	2019
Saku K, Tahara N, Takaseya T, Shintani Y, Takagi K, Shojima T, Kurata S, Fujimoto K, Abe T, Fukumoto Y, Tanaka H	Multimodal imaging of cardiac-calcified amorphous tumor.	J Nucl Cardiol	27(2)	682-685	2020
Tahara N, Bekki M, Sugiyama Y, Tahara A, Fukumoto Y	Importance of extracardiac FDG uptake to diagnose cardiac sarcoidosis.	J Nucl Cardiol	27(1)	118-122	2020
Maeda S, Tahara N, Takase F, Bekki M, Tahara A, Honda A, Igata S, Sugiyama Y, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Fukumoto Y	Diagnostic performance of FDG-PET/CTA in native mitral valve endocarditis.	J Nucl Cardiol	26(2)	681-683	2019
Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI	Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.	Curr Vasc Pharmacol	17(4)	411-420	2019

Bekki M, Tahara N, Tahara A, Honda A, Igata S, Sugiyama Y, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Tanaka H, Suda K, Fukumoto Y	Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease.	J Nucl Cardiol	26(2)	671-673	2019
Saku K, Shintani Y, Tahara N, Kikusaki S, Imai S, Shojima T, Takagi K, Kurata S, Fujimoto K, Abe T, Fukumoto Y, Tanaka H	Inflammatory reaction of a pericardial foreign body after cardiac surgery.	J Nucl Cardiol	26(1)	328-329	2019
本多亮博, 田原宣広, 田原敦子, 戸次宗久, 緒方詔子, 杉山陽一, 井形幸代, 福本義弘	動脈硬化関連検査.	臨牀と研究	96(8)	951-957	2019
枚山陽一, 田原宣広, 福本義弘	左心疾患に伴う肺高血圧症の分類と治療の動向.	呼吸器ジャーナル	67(4)	650-659	2019
田原宣広, 田原敦子, 戸次宗久, 前田(緒方)詔子, 枚山陽一, 孫佳慧, 本多亮博, 井形幸代, 福本義弘	PETによる動脈硬化の炎症活動性評価 - 今後の臨床的意義.	循環器内科	86(3)	322-331	2019
田原宣広, 甲斐久史, 福本義弘	RI検査 (PET).	日本医師会雑誌	148(2)	173-175	2019
田原宣広, 田原敦子, 戸次宗久, 枚山陽一, 緒方詔子, 本多亮博, 山岸昌一, 福本義弘	AGEsと心血管病.	WHITE	7(2)	16-21	2019
田原宣広, 前田(緒方)詔子, 戸次宗久, 枚山陽一, 本多亮博, 井形幸代, 田原敦子, 福本義弘	アミロイドーシスとサルコイドーシスにおける核医学の使い方.	RadFan	17(9)	45-48	2019